StocksFundsScreenerSectorsWatchlists
NVAX

NVAX - Novavax Inc Stock Price, Fair Value and News

3.99USD+0.10 (+2.57%)Market Closed

Market Summary

NVAX
USD3.99+0.10
Market Closed
2.57%

NVAX Stock Price

View Fullscreen

NVAX RSI Chart

NVAX Valuation

Market Cap

544.4M

Price/Earnings (Trailing)

-1

Price/Sales (Trailing)

0.55

EV/EBITDA

0.05

Price/Free Cashflow

-0.76

NVAX Price/Sales (Trailing)

NVAX Profitability

Operating Margin

65.05%

EBT Margin

-55.20%

Return on Equity

76.03%

Return on Assets

-30.32%

Free Cashflow Yield

-131.14%

NVAX Fundamentals

NVAX Revenue

Revenue (TTM)

983.7M

Rev. Growth (Yr)

-18.48%

Rev. Growth (Qtr)

55.81%

NVAX Earnings

Earnings (TTM)

-545.1M

Earnings Growth (Yr)

2.12%

Earnings Growth (Qtr)

-36.41%

Breaking Down NVAX Revenue

Last 7 days

-9.5%

Last 30 days

-21.3%

Last 90 days

-3.9%

Trailing 12 Months

-56.6%

How does NVAX drawdown profile look like?

NVAX Financial Health

Current Ratio

0.7

NVAX Investor Care

Shares Dilution (1Y)

62.41%

Diluted EPS (TTM)

-5.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.4B1.6B1.0B983.7M
20221.4B1.3B1.8B2.0B
2021919.5M1.2B1.2B1.1B
202018.1M50.2M204.8M475.6M
201928.6M21.2M16.0M18.7M
201835.1M39.2M38.6M34.3M
201716.8M21.0M26.2M31.2M
201630.6M19.1M15.8M15.4M
201533.1M38.8M37.1M36.3M
201424.5M29.3M32.7M30.7M
201321.3M17.7M16.7M20.9M
201218.5M22.6M23.4M22.1M
20112.2M4.1M8.9M14.7M
20100331.0K337.0K343.0K
2009000325.0K

Tracking the Latest Insider Buys and Sells of Novavax Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 10, 2024
dubovsky filip
sold (taxes)
-14,153
5.45
-2,597
president, r&d
Mar 10, 2024
kelly james patrick
sold (taxes)
-12,131
5.45
-2,226
evp, cfo and treasurer
Mar 10, 2024
trizzino john
sold (taxes)
-12,131
5.45
-2,226
president and coo
Mar 10, 2024
dubovsky filip
acquired
-
-
5,376
president, r&d
Mar 10, 2024
kelly james patrick
acquired
-
-
4,608
evp, cfo and treasurer
Mar 10, 2024
trizzino john
acquired
-
-
4,608
president and coo
Mar 07, 2024
kelly james patrick
sold (taxes)
-33,127
5.61
-5,905
evp, cfo and treasurer
Mar 07, 2024
dubovsky filip
sold (taxes)
-52,689
5.61
-9,392
president, r&d
Mar 07, 2024
dubovsky filip
acquired
-
-
19,444
president, r&d
Mar 07, 2024
trizzino john
sold (taxes)
-78,287
5.61
-13,955
evp, cco and cbo

1–10 of 50

Which funds bought or sold NVAX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
PayPay Securities Corp
added
89.68
3,059
6,501
0.32%
Apr 17, 2024
Hennion & Walsh Asset Management, Inc.
added
7.12
4,229
67,565
-%
Apr 17, 2024
Stephens Consulting, LLC
sold off
-100
-4,800
-
-%
Apr 17, 2024
Private Ocean, LLC
sold off
-100
-653
-
-%
Apr 16, 2024
Edge Wealth Management LLC
unchanged
-
-300
71,700
0.01%
Apr 16, 2024
Arlington Trust Co LLC
sold off
-100
-696
-
-%
Apr 16, 2024
Asset Dedication, LLC
unchanged
-
-
-
-%
Apr 16, 2024
Independence Bank of Kentucky
unchanged
-
-3.00
679
-%
Apr 15, 2024
Sound Income Strategies, LLC
unchanged
-
-1.00
335
-%
Apr 12, 2024
HARBOR INVESTMENT ADVISORY, LLC
unchanged
-
-15.00
3,647
-%

1–10 of 41

Are Funds Buying or Selling NVAX?

Are funds buying NVAX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NVAX
No. of Funds

Unveiling Novavax Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 15, 2024
shah capital management
6.66%
9,326,176
SC 13D
Apr 15, 2024
shah capital management
6.66%
9,326,176
SC 13D/A
Mar 07, 2024
morgan stanley
1.8%
2,454,328
SC 13G/A
Feb 13, 2024
vanguard group inc
12.26%
14,560,054
SC 13G/A
Feb 09, 2024
morgan stanley
6.2%
7,308,033
SC 13G
Jan 26, 2024
blackrock inc.
7.1%
8,436,179
SC 13G/A
Jan 25, 2024
state street corp
14.12%
16,775,875
SC 13G/A
Aug 18, 2023
sk bioscience co., ltd.
6.4%
6,500,000
SC 13G
May 10, 2023
state street corp
12.11%
10,452,512
SC 13G/A
Apr 27, 2023
shah capital management
5.28%
4,550,756
SC 13D

Recent SEC filings of Novavax Inc

View All Filings
Date Filed Form Type Document
Apr 15, 2024
SC 13D
13D - Major Acquisition
Apr 15, 2024
SC 13D/A
13D - Major Acquisition
Mar 26, 2024
4
Insider Trading
Mar 26, 2024
4
Insider Trading
Mar 26, 2024
4
Insider Trading
Mar 26, 2024
4
Insider Trading
Mar 26, 2024
4
Insider Trading
Mar 26, 2024
4
Insider Trading
Mar 26, 2024
8-K
Current Report
Mar 12, 2024
4
Insider Trading

Peers (Alternatives to Novavax Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
39.0B
6.8B
-2.93% -28.56%
-8.27
5.69
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.3B
1.8B
-2.14% -28.32%
-41.48
9.99
76.23% 61.08%
17.0B
2.4B
5.64% -9.07%
101.38
7.03
15.42% 18.43%
11.9B
3.7B
-9.46% -28.45%
19.84
3.21
8.87% 75.42%
MID-CAP
5.7B
396.6M
-16.55% -42.15%
-10.84
14.45
425.83% 18.94%
4.4B
-
-12.14% 49.76%
-6.72
60.35
54.84% -34.79%
3.1B
270.6M
-14.48% -8.88%
-13.01
11.51
440.80% -27.84%
2.8B
726.4M
-8.72% -14.74%
-45.89
3.87
40.45% 71.62%
2.8B
240.7M
-18.65% -25.84%
-9.44
12.18
-1.03% -92.09%
SMALL-CAP
1.8B
398.2M
-6.41% -11.48%
25.32
4.54
85.90% -14.05%
544.4M
983.7M
-21.26% -56.58%
-1
0.55
-50.36% 17.16%
382.8M
881.7K
-14.69% 262.26%
-8.58
466.16
-77.61% -5.33%
238.4M
4.9M
-4.49% -3.41%
-1.76
48.98
-54.97% 51.71%
6.2M
2.1M
67.92% 36.92%
-0.23
2.14
-13.45% 66.37%

Novavax Inc News

Latest updates
MarketWatch24 hours ago
Defense World17 Apr 202410:03 am
Yahoo Movies Canada16 Apr 202409:14 am
MarketBeat15 Apr 202404:58 pm
Seeking Alpha15 Apr 202411:48 am
Investor's Business Daily2 months ago

Novavax Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue55.8%291,342,000186,986,000424,426,00080,951,000357,399,000734,577,000185,925,000703,971,000222,200,000178,844,000298,017,000447,229,000279,659,000157,024,00035,538,0003,377,0008,816,0002,507,0003,357,0003,982,0006,127,000
Cost Of Revenue56.7%154,976,00098,929,00055,777,00034,086,000181,765,000434,593,000271,077,00015,204,000-------------
Costs and Expenses51.9%474,910,000312,618,000368,969,000393,719,000601,278,000861,766,000668,885,000494,679,0001,047,171,000485,988,000643,846,000655,861,000462,512,000350,966,00052,565,00026,274,00037,521,00017,494,00040,023,00044,205,00052,639,000
  S&GA Expenses44.5%155,237,000107,460,00093,717,000112,532,000161,663,000122,876,000108,160,00095,992,00084,214,00077,793,00073,161,00063,190,00061,313,00056,879,00017,719,0009,379,0008,180,5007,899,0009,606,0008,732,0009,224,000
  R&D Expenses55.0%164,697,000106,229,000219,475,000247,101,000257,850,000304,297,000289,648,000383,483,000962,957,000408,195,000570,685,000592,671,000401,199,000294,087,00034,846,00016,895,00029,340,50018,611,00030,417,00035,473,00043,415,000
EBITDA Margin-4.4%-0.50-0.47-0.33-0.81-0.31-0.68-1.09-0.89-1.47-0.86-0.78-0.64---------
Interest Expenses44.0%4,117,0002,859,0003,124,0004,316,0004,601,0004,169,0006,234,0004,876,0005,138,0005,182,0005,968,0004,839,0003,879,0004,460,0003,403,0003,403,0003,403,0003,403,0003,403,0003,403,0003,403,000
Income Taxes342.2%1,688,000-697,000-143,0001,183,000-2,260,0002,472,0001,418,0002,662,00016,609,0006,041,0003,548,0003,017,000---------
Earnings Before Taxes-34.4%-176,701,000-131,473,00057,865,000-292,722,000-184,509,000-166,141,000-509,067,000206,070,000-829,675,000-316,390,000-348,769,000-219,702,000-177,564,000-197,310,000-17,521,000------
EBT Margin-5.2%-0.55-0.52-0.37-0.85-0.33-0.70-1.12-0.92-1.50-0.88-0.80-0.67---------
Net Income-36.4%-178,389,000-130,776,00058,008,000-293,905,000-182,249,000-168,613,000-510,485,000203,408,000-846,284,000-322,431,000-352,317,000-222,719,000-177,564,000-197,310,000-17,521,000-25,864,000-31,830,000-18,043,000-39,603,000-43,218,000-49,334,000
Net Income Margin-6.0%-0.55-0.52-0.37-0.85-0.33-0.72-1.14-0.94-1.52-0.89-0.80-0.67---------
Free Cashflow-345.6%-176,767,000-39,669,000-193,949,000-347,604,000-139,790,000-60,719,000-184,610,333-102,217,333-356,115,333-155,850,333-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets8.5%1,7971,6571,6851,5432,2592,2672,6232,8352,5772,5662,7502,6081,582944932328173165189221208
  Current Assets13.6%1,1441,0071,1289711,7031,7602,1362,3472,1552,1742,3552,2471,24867163625597.0089.00110123119
    Cash Equivalents-12.7%5696515066251,3371,2931,3881,5841,5151,9472,1232,02964940253218782.0076.0078.0010682.00
  Inventory-40.1%42.0070.0023.0034.0037.0082.002561079.00------------
  Net PPE1.6%30630130030729425625524722621521319218013211511.0011.0012.0013.0027.0028.00
  Goodwill3.0%12712412813012611812313113113213413113512711950.0051.0050.0051.0051.0052.00
Liabilities7.7%2,5142,3362,4402,4382,8932,8333,0402,7702,9282,1052,0041,569955638548352359355375372376
  Current Liabilities11.3%1,6351,4691,5961,9192,4601,6682,1562,2612,3901,7531,6521,20958023921319.0026.0022.0041.0031.0046.00
Shareholder's Equity-Infinity%-716----634--65.00-3514617461,039627106185------
  Retained Earnings-3.8%-4,820-4,642-4,511-4,569-4,275-4,093-3,925-3,414-3,617-2,771-2,449-2,096-1,874-1,696-1,499-1,457-1,431-1,399-1,381-1,342-1,299
  Additional Paid-In Capital3.1%4,1924,0673,8563,7683,7383,6413,6053,5663,3523,3113,2373,1802,5351,8491,6991,4501,2611,2261,2111,2021,145
Shares Outstanding17.5%14011994.0086.0086.0078.0078.0076.0074.0074.0074.0073.00---------
Float---699---4,010---15,697---5,079---138--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-345.6%-176-39.67-171-325-117-38.71-170-88.51-342-142144663-128-6.50116-23.11-23.74-32.26-30.01-50.61-45.27
  Share Based Compensation-24.6%16.0021.0020.0029.0028.0032.0038.0033.0032.0045.0053.0053.0050.0066.008.004.004.003.005.006.004.00
Cashflow From Investing50.6%-9.08-18.39-7.78-23.56-22.06-29.52-24.58-16.83-16.36-12.19-12.90142-31.12-100-188-57.73-0.2218.002.0019.0048.00
Cashflow From Financing-49.1%10019761.00-354191-30.985.00160-60.71-15.72-38.84577405-22.3941718630.0012.000.0056.004.00

NVAX Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Revenues$ 983,705$ 1,981,872$ 1,146,290
Expenses:   
Cost of sales343,768902,6390
Research and development737,5021,235,2782,534,508
Selling, general, and administrative468,946488,691298,358
Total expenses1,550,2162,626,6082,832,866
Loss from operations(566,511)(644,736)(1,686,576)
Other income (expense):   
Interest expense(14,416)(19,880)(21,127)
Other income (expense)37,89610,969(6,833)
Loss before income tax expense(543,031)(653,647)(1,714,536)
Income tax expense(2,031)(4,292)(29,215)
Net loss$ (545,062)$ (657,939)$ (1,743,751)
Net loss per share:   
Basic (in usd per share)$ (5.41)$ (8.42)$ (23.44)
Diluted (in usd per share)$ (5.41)$ (8.42)$ (23.44)
Weighted average number of common shares outstanding:   
Basic (in shares)100,76878,18374,400
Diluted (in shares)100,76878,18374,400
Product sales   
Revenue:   
Revenues$ 531,389$ 1,554,961$ 0
Grants   
Revenue:   
Revenues427,323382,921948,709
Royalties and other   
Revenue:   
Revenues$ 24,993$ 43,990$ 197,581

NVAX Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 568,505$ 1,336,883
Restricted cash10,42410,303
Accounts receivable297,24082,375
Inventory41,69636,683
Prepaid expenses and other current assets226,023237,147
Total current assets1,143,8881,703,391
Property and equipment, net305,771294,247
Right of use asset, net185,218106,241
Goodwill127,454126,331
Other non-current assets35,15928,469
Total assets1,797,4902,258,679
Current liabilities:  
Accounts payable132,610216,517
Accrued expenses394,668591,158
Deferred revenue241,310370,137
Current portion of finance lease liabilities5,14227,196
Convertible notes payable0324,881
Other current liabilities861,408930,055
Total current liabilities1,635,1382,459,944
Deferred revenue622,210179,414
Convertible notes payable168,016166,466
Non-current finance lease liabilities55,92331,238
Other non-current liabilities33,13055,695
Total liabilities2,514,4172,892,757
Commitments and contingencies (Note 16)
Preferred stock, $0.01 par value, 2,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 202200
Stockholders’ deficit:  
Common stock, $0.01 par value, 600,000,000 shares authorized at December 31, 2023 and 2022; and 140,506,093 shares issued and 139,505,770 shares outstanding at December 31, 2023 and 86,806,554 shares issued and 86,039,923 shares outstanding at December 31, 20221,405868
Additional paid-in capital4,192,1643,737,979
Accumulated deficit(4,820,951)(4,275,889)
Treasury stock, 1,000,323 shares, cost basis at December 31, 2023 and 766,631 shares, cost basis at December 31, 2022(92,267)(90,659)
Accumulated other comprehensive income (loss)2,722(6,377)
Total stockholders’ deficit(716,927)(634,078)
Total liabilities and stockholders’ deficit$ 1,797,490$ 2,258,679
NVAX
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
 CEO
 WEBSITEnovavax.com
 INDUSTRYBiotechnology
 EMPLOYEES1992

Novavax Inc Frequently Asked Questions


What is the ticker symbol for Novavax Inc? What does NVAX stand for in stocks?

NVAX is the stock ticker symbol of Novavax Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Novavax Inc (NVAX)?

As of Thu Apr 18 2024, market cap of Novavax Inc is 544.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVAX stock?

You can check NVAX's fair value in chart for subscribers.

What is the fair value of NVAX stock?

You can check NVAX's fair value in chart for subscribers. The fair value of Novavax Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Novavax Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NVAX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Novavax Inc a good stock to buy?

The fair value guage provides a quick view whether NVAX is over valued or under valued. Whether Novavax Inc is cheap or expensive depends on the assumptions which impact Novavax Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVAX.

What is Novavax Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, NVAX's PE ratio (Price to Earnings) is -1 and Price to Sales (PS) ratio is 0.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVAX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Novavax Inc's stock?

In the past 10 years, Novavax Inc has provided -0.264 (multiply by 100 for percentage) rate of return.